Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $36.40 USD
Change Today -1.16 / -3.10%
Volume 688.2K
MYGN On Other Exchanges
Symbol
Exchange
Frankfurt
As of 2:01 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

320 Wakara Way

Salt Lake City, UT 84108

United States

Phone: 801-584-3600

Fax: 801-584-3640

ight be used throughout the course of a patient’s disease and provides clinicians with expanded insight on disease severity and the risk of radiographic progression. Prolaris: RNA expression test for assessing the aggressiveness of prostate cancer. The company’s Prolaris test is a gene expression assay that assesses whether a patient is likely to have a slow growing, indolent form of prostate cancer that could be monitored through active surveillance, or a more aggressive form of the disease that would warrant aggressive intervention, such as a radical prostatectomy or radiation therapy. EndoPredict: RNA expression test for assessing the aggressiveness of breast cancer. The EndoPredict test, licensed for distribution outside the U.S., is a next-generation RNA expression test used to determine which women with breast cancer would benefit from chemotherapy. EndoPredict predicts the likelihood of metastases to help guide treatment decisions for chemotherapy and extended anti-hormonal therapy. EndoPredict has been shown to predict cancer-specific disease progression and metastases with no confusing intermediate results in 13 published clinical studies with approximately 2,200 patients and is CE marked. myPath Melanoma: RNA expression test for diagnosing melanoma. The company’s myPath Melanoma test is a gene expression based profile that is performed on biopsy tissue for the purpose of aiding a dermatopathologist in the diagnosis of melanoma. myPath Melanoma might provide a tool to assist physicians in correctly diagnosing indeterminate skin lesions. myPath Melanoma was released through an early access launch that began in 2013. myPlan Lung Cancer: RNA expression test for assessing the aggressiveness of lung cancer. The company’s myPlan Lung Cancer test is a gene expression based profile that might aid a physician in making a determination as to the aggressiveness of a patient’s lung cancer and based upon this determination more accurately guide patient therapy. Most early stage lung cancer patients do not see added benefit from chemotherapy. myPlan Lung Cancer was released through an early access launch that began in 2013. Pharmaceutical and Clinical Services The company’s pharmaceutical and clinical services consist of the following: The company, through Myriad RBM, provides biomarker discovery and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries utilizing its multiplexed immunoassay technology. The company’s technology enables it to screen large sets of well-characterized clinical samples from both diseased and non-diseased populations against its extensive menu of biomarkers. In February 2015, the company completed the acquisition of Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG (the ‘Clinic’) located approximately 15 miles from the company’s European laboratories in Munich, Germany. The acquisition of the Clinic should facilitate the company’s penetration into the German molecular diagnostic market. The Clinic would allow the company to directly negotiate reimbursement with government and private insurance providers for its tests in the German market and collaborate with hospitals and physician groups. Sales and Marketing The company plans to sell its tests through its own direct sales force and marketing efforts in the United States, Europe, Australia, and Canada. The company’s United States sales force includes approximately 590 individuals across 5 separate sales channels. In connection with any additional tests that the company might launch, it plans to expand its existing oncology, preventive care, urology, dermatology, and autoimmune care sales forces; and build new sales forces to address other physician specialty groups. The company has distributor agreements with organizations in selected European, Latin American, the Middle Eastern, Asian, and African countries. License Agreements The company’s subsidiary, Crescendo Bioscience, Inc., has a license agreement with the Oklahoma Medical Research Foundation (the ‘OMRF), for the exclusive worldwide right to utilize certain intellectual property rights of OMRF, including p

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYGN:US $36.42 USD -1.13

MYGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanced Drainage Systems Inc $28.30 USD -0.11
Alliance HealthCare Services Inc $14.03 USD -0.29
Genomic Health Inc $26.24 USD -1.28
RadNet Inc $5.92 USD -0.225
View Industry Companies
 

Industry Analysis

MYGN

Industry Average

Valuation MYGN Industry Range
Price/Earnings 33.8x
Price/Sales 3.5x
Price/Book 3.8x
Price/Cash Flow 31.2x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYRIAD GENETICS INC, please visit www.myriad.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.